Does Including Informal Care in Economic Evaluations Matter? A Systematic Review of Inclusion and Impact of Informal Care in Cost-Effectiveness Studies

PharmacoEconomics

Volumn 33, Issue 2, 2015, Pages 123-135

  Krol, Marieke ^a   Papenburg, Jocé ^b   van Exel, Job ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b Independent researcher   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; CONTRAST MEDIUM; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DONEPEZIL; ETANERCEPT; GALANTAMINE; MEMANTINE; MIRTAZAPINE; PRAMIPEXOLE; RASAGILINE; RITUXIMAB; RIVASTIGMINE; SERTRALINE; TUMOR NECROSIS FACTOR INHIBITOR;

ALZHEIMER DISEASE; CAREGIVER; CAREGIVER BURDEN; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DAILY LIFE ACTIVITY; DEMENTIA; DEPRESSION; EARLY DIAGNOSIS; ECONOMIC EVALUATION; HEALTH CARE COST; HUMAN; INFORMAL CARE; METASTATIC COLORECTAL CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PARKINSON DISEASE; PATIENT CARE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; WELLBEING; COST BENEFIT ANALYSIS; ECONOMICS; TIME;

CAREGIVERS; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HUMANS; PATIENT CARE; TIME FACTORS;

EID: 84921793887     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-014-0218-y     Document Type: Review

References (47)

1. Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford/New York: Oxford University Press; 2005.
2. Basu A, Meltzer D. Implications of spillover effects within the family for medical cost-effectiveness analysis. J Health Econ. 2005;24:751–73.
3. Christakis NA. Social networks and collateral health effects. BMJ. 2004;329:184–5.
4. Bobinac A, van Exel NJ, Rutten FF, Brouwer WB. Caring for and caring about: disentangling the caregiver effect and the family effect. J Health Econ. 2010;29:549–56.
5. Bobinac A, van Exel NJ, Rutten FF, Brouwer WB. Health effects in significant others: separating family and care-giving effects. Med Decis Making. 2011;31:292–8.
6. Hoefman RJ, van Exel J, Brouwer W. How to include informal care in economic evaluations. Pharmacoeconomics. 2013;31:1105–19.
7. Schulz R, Beach SR. Caregiving as a risk factor for mortality: the Caregiver Health Effects Study. JAMA. 1999;282:2215–9.
8. Pitsenberger DJ. Juggling work and elder caregiving: work-life balance for aging American workers. AAOHN J. 2006;54:181–5 (quiz 186–7).
9. van Ryn M, Sanders S, Kahn K, van Houtven C, Griffin JM, Martin M, et al. Objective burden, resources, and other stressors among informal cancer caregivers: a hidden quality issue? Psychooncology. 2011;20:44–52.
10. Brouwer WB. Too important to ignore: informal caregivers and other significant others. Pharmacoeconomics. 2006;24:39–41.
11. Dixon S, Walker M, Salek S. Incorporating carer effects into economic evaluation. Pharmacoeconomics. 2006;24:43–53.
12. Davidson T, Levin LA. Is the societal approach wide enough to include relatives? Incorporating relatives’ costs and effects in a cost-effectiveness analysis. Appl Health Econ Health Policy. 2010;8:25–35.
13. Al-Janabi H, Flynn TN, Coast J. QALYs and carers. Pharmacoeconomics. 2011;29:1015–23.
14. Koopmanschap MA, van Exel JN, van den Berg B, Brouwer WB. An overview of methods and applications to value informal care in economic evaluations of healthcare. Pharmacoeconomics. 2008;26:269–80.
15. Goodrich K, Kaambwa B, Al-Janabi H. The inclusion of informal care in applied economic evaluation: a review. Value Health. 2012;15:975–81.
16. Opara JA. Activities of daily living and quality of life in Alzheimer disease. J Med Life. 2012;5:162–7.
17. Schrag A, Hovris A, Morley D, Quinn N, Jahanshahi M. Caregiver-burden in Parkinson’s disease is closely associated with psychiatric symptoms, falls, and disability. Parkinsonism Relat Disord. 2006;12:35–41.
18. Sansoni J, Anderson KH, Varona LM, Varela G. Caregivers of Alzheimer’s patients and factors influencing institutionalization of loved ones: some considerations on existing literature. Ann Ig. 2013;25:235–46.
19. Birnbaum H, Pike C, Kaufman R, Marynchenko M, Kidolezi Y, Cifaldi M. Societal cost of rheumatoid arthritis patients in the US. Curr Med Res Opin. 2010;26:77–90.
20. Brouwer WB, van Exel NJ, van de Berg B, Dinant HJ, Koopmanschap MA, van den Bos GA. Burden of caregiving: evidence of objective burden, subjective burden, and quality of life impacts on informal caregivers of patients with rheumatoid arthritis. Arthritis Rheum. 2004;51:570–7.
21. Dalal KM, Gollub MJ, Miner TJ, Wong WD, Gerdes H, Schattner MA, et al. Management of patients with malignant bowel obstruction and stage IV colorectal cancer. J Palliat Med. 2011;14:822–8.
22. Gao W, Gulliford M, Bennett MI, Murtagh FE, Higginson IJ. Managing cancer pain at the end of life with multiple strong opioids: a population-based retrospective cohort study in primary care. PLoS One. 2014;9:e79266.
23. Stone PW, Chapman RH, Sandberg EA, Liljas B, Neumann PJ. Measuring costs in cost-utility analyses. Variations in the literature. Int J Technol Assess Health Care. 2000;16:111–24.
24. Hoefman RJ, Van Exel NJA, Brouwer WBF. iMTA Valuation of Informal Care Questionnaire (iVICQ). Version 1.0 (December 2011). Rotterdam: iBMG/iMTA; 2011. http://www.bmg.eur.nl/english/imta/publications/manuals_questionnaires/#iVICQ. Accessed 12 Apr 2014.
25. Rive B, Aarsland D, Grishchenko M, Cochran J, Lamure M, Toumi M. Cost-effectiveness of memantine in moderate and severe Alzheimer’s disease in Norway. Int J Geriatr Psychiatry. 2012;27:573–82.
26. Meeuwsen E, Melis R, van der Aa G, Goluke-Willemse G, de Leest B, van Raak F, et al. Cost-effectiveness of one year dementia follow-up care by memory clinics or general practitioners: economic evaluation of a randomised controlled trial. PLoS One. 2013;8:e79797.
27. Touchon J, Lachaine J, Beauchemin C, Granghaud A, Rive B, Bineau S. The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer’s disease to nursing homes: cost-effectiveness analysis in France. Eur J Health Econ. Epub 2013 Aug 9.
28. Getsios D, Blume S, Ishak KJ, Maclaine G, Hernandez L. An economic evaluation of early assessment for Alzheimer’s disease in the United Kingdom. Alzheimers Dement. 2012;8:22–30.
29. Pfeil AM, Kressig RW, Szucs TD. Alzheimer’s dementia: budget impact and cost-utility analysis of a combination treatment of a cholinesterase inhibitor and memantine in Switzerland. Swiss Med Wkly. 2012;142:w13676.
30. López-Bastida J, Hart W, Garcia-Perez L, Linertova R. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer’s disease. J Alzheimers Dis. 2009;16:399–407.
31. Zhang Y, Kivipelto M, Solomon A, Wimo A. Cost-effectiveness of a health intervention program with risk reductions for getting demented: results of a Markov model in a Swedish/Finnish setting. J Alzheimers Dis. 2011;26:735–44.
32. Hoogveldt B, Rive B, Severens J, Maman K, Guilhaume C. Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer’s disease in The Netherlands. Neuropsychiatr Dis Treat. 2011;7:313–7.
33. Biasutti M, Dufour N, Ferroud C, Dab W, Temime L. Cost-effectiveness of magnetic resonance imaging with a new contrast agent for the early diagnosis of Alzheimer’s disease. PLoS One. 2012;7:e35559.
34. van den Hout WB, Goekoop-Ruiterman YP, Allaart CF, de Vries-Bouwstra JK, Hazes JM, Kerstens PJ, et al. Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis. Arthritis Rheum. 2009;61:291–9.
35. Lekander I, Borgstrom F, Svarvar P, Ljung T, Carli C, van Vollenhoven RF. Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden. Int J Technol Assess Health Care. 2010;26:54–61.
36. Ungar WJ, Costa V, Hancock-Howard R, Feldman BM, Laxer RM. Cost-effectiveness of biologics in polyarticular-course juvenile idiopathic arthritis patients unresponsive to disease-modifying antirheumatic drugs. Arthritis Care Res. 2011;63:111–9.
37. Kobelt G, Lekander I, Lang A, Raffeiner B, Botsios C, Geborek P. Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment. Int J Technol Assess Health Care. 2011;27:193–200.
38. Lekander I, Borgstrom F, Lysholm J, van Vollenhoven RF, Lindblad S, Geborek P, et al. The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice. Eur J Health Econ. 2013;14:863–73.
39. Lindgren P, Geborek P, Kobelt G. Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden. Int J Technol Assess Health Care. 2009;25:181–9.
40. Hartz S, Getsios D, Tao S, Blume S, Maclaine G. Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer’s disease in Germany using discrete event simulation. BMC Neurol. 2012;12:2.
41. Bond M, Rogers G, Peters J, Anderson R, Hoyle M, Miners A, et al. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (review of Technology Appraisal no. 111): a systematic review and economic model. Health Technol Assess. 2012;16:1–470.
42. Woods RT, Bruce E, Edwards RT, Elvish R, Hoare Z, Hounsome B, et al. REMCARE: reminiscence groups for people with dementia and their family caregivers—effectiveness and cost-effectiveness pragmatic multicentre randomised trial. Health Technol. Assess. 2012;16:v–xv (1–116).
43. Banerjee S, Hellier J, Romeo R, Dewey M, Knapp M, Ballard C, et al. Study of the use of antidepressants for depression in dementia: the HTA-SADD trial—a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine. Health Technol Assess. 2013;17:1–166.
44. Nagy B, Brennan A, Brandtmuller A, Thomas SK, Sullivan SD, Akehurst R. Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer’s disease in the UK using MMSE- and ADL-based models. Int J Geriatr Psychiatry. 2011;26:483–94.
45. Romeo R, Knapp M, Hellier J, Dewey M, Ballard C, Baldwin R, et al. Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. Br J Psychiatry. 2013;202:121–8.
46. Haycox A, Armand C, Murteira S, Cochran J, Francois C. Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson’s disease in the UK setting: an economic Markov model evaluation. Drugs Aging. 2009;26:791–801.
47. Suh GH. Modeling the cost-effectiveness of galantamine for mild to moderately severe Alzheimer’s disease in Korea. Value Health. 2009;12:S49–54.